noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

Pharmaceuticals and Biotechnology

Spanish Agency for Medicines and[...]

La AEMPS informa del cese de comercialización, retirada del mercado y[...]
Synakis Corp

Synakis Co-Founder Molly Shoichet Elected a Fellow of the National[...]
Synakis Corp

Synakis Selected for Medicine by Design’s Building a Biotech Venture[...]

Economy, Business and Finance

Synakis Corp

02/03/2026 | Press release | Archived content

Synakis Engages Community at Ophthalmic Drug Delivery Summit, Glaucoma 360, and OBIO Investment Summit

February 3, 2026

Synakis CEO Thierry Nivaggioli presented at the 4th Annual Ophthalmic Drug Delivery Summit (ODDS), January 27-29, 2026, in San Francisco, CA. The summit brought together experts in the field to discuss the future of ophthalmic therapies.

Synakis Corp published this content on February 03, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 02, 2026 at 06:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format